Open AccessFirst Use of a New Extracorporeal Membrane Oxygenation System in COVID19-Associated Adult Respiratory Distress Syndrome: The MobyBox Device
Author(s) -
Miriam Kau,
Jens C Steltner,
Philipp M. Lepper,
Albert Omlor,
Sebastian Mang,
Jovan Misic,
AA Peivandi,
Ralf Michael Muellenbach,
Christian Reyher
Publication year - 2022
Publication title -
asaio journal
Language(s) - English
Resource type - Journals
eISSN - 1538-943X
pISSN - 1058-2916
DOI - 10.1097/mat.0000000000001685
Subject(s) - extracorporeal membrane oxygenation , ards , medicine , intensive care medicine , covid-19 , oxygenation , acute respiratory distress , respiratory distress , respiratory failure , anesthesia , lung , disease , infectious disease (medical specialty)
In late 2020, during the second wave of COVID-19 in Germany, we started using the MobyBox, which is a novel fully pneumatically driven ECMO device, on a regular basis to meet the increasing demand for ECMO therapy. In this case series, we performed a retrospective chart review of seven patients with severe COVID-19-related acute respiratory distress syndrome (ARDS) requiring veno-venous (vv)-ECMO support with the MobyBox. During ECMO treatments we have observed no disadvantages in comparison to conventional ECMO systems. There were no system failures or adverse events directly attributable to the MobyBox system. Our data support that providing vv-ECMO with the MobyBox device is safe and feasible. Furthermore, our findings suggest that the MobyBox device might represent an advantage in terms of biocompatibility. Therefore, more data on this issue is needed to better understand how the pneumatically driven pump affects cellular blood components.